26 October 2016
By Maynard Paton
Quick update on Bioventix (BVXP).
Event: Preliminary results and shareholder presentation for the year to 30 June 2016 published 17 October 2016
Summary: The antibody developer had already said this statement would reveal bumper results, but the figures were still better than I had expected. Although progress was helped by post-Brexit currency movements, it was clear the underlying business delivered yet another robust performance. The financials remain extremely impressive, with the second-half operating margin hitting an incredible 80%. The icing on the cake was management underpinning its confidence with the declaration of a welcome £1m special dividend. I continue to hold.